Purpose of Review <p>This review explores the genetic basis of kidney diseases and highlights emerging technologies in nephrogenetics. It examines how advances in single-cell RNA sequencing (scRNA-seq), kidney organoid models, and artificial intelligence (AI) are transforming disease diagnosis, treatment, and personalized medicine.</p> Recent Findings <p>Innovations in scRNA-seq have provided cell-specific insights into gene expression changes in kidney diseases, aiding biomarker discovery and disease mechanism understanding. Kidney organoids, derived from stem cells, effectively model kidney diseases, enabling drug screening and therapeutic advancements. AI-driven genetic analysis enhances disease prediction and treatment optimization. These breakthroughs bridge the gap between basic research and clinical applications, paving the way for precision nephrology.</p> Summary <p>The integration of nephrogenetic research with clinical practice holds significant potential for improving patient outcomes. While challenges remain, including ethical considerations and large-scale validation studies, these technologies promise earlier diagnoses, personalized treatments, and novel therapeutic targets, ultimately advancing kidney disease management.</p>